TITLE

Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy

AUTHOR(S)
McPherson, Christopher; Gerena-Lewis, Margie; Breneman, John; Warnick, Ronald
PUB. DATE
July 2012
SOURCE
Journal of Neuro-Oncology;Jul2012, Vol. 108 Issue 3, p521
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Previously we demonstrated median survival of 69 weeks after combination therapy of permanent, low-activity I-125 seeds and BCNU wafers for recurrent glioblastoma multiforme (GBM). We designed this prospective phase I trial to assess efficacy of this combination treatment for newly diagnosed GBM. Patients with newly diagnosed GBMs deemed amenable to gross total resection were included. This dose-escalation study of I-125 seeds included three 6-patient cohorts, receiving increasing doses of 3000, 6000, and 9000 cGy, and a maximal number of BCNU wafers placed surgically. Postoperatively patients underwent standard fractionated radiation to 5,940 cGy followed by temozolomide chemotherapy. During enrollment of the first 6-patient cohort, the trial was stopped when 3 of 5 patients developed radiation toxicity. Five patients (median age 55 years, range 46-64 years) completed postoperative radiation; Karnofsky Performance Status ranged from 70 to 90. This lowest-dose cohort received I-125 seeds at 3,000 cGy and maximal BCNU wafer placement, and reached endpoint (median 26 weeks follow-up). Two patients developed local disease progression (median 34.4 weeks). The 3 patients who developed radiation toxicity, which was documented on follow-up MRI and confirmed by MRI spectroscopy (median 20 weeks), underwent treatment with steroids and bevacizumab. Our phase I study was closed during enrollment of the first 6-patient cohort because of the high incidence (60 %) of early radiation toxicity. We do not recommend the seed-wafer therapy for newly diagnosed GBM patients but rather reserve this as salvage therapy for select patients with recurrent GBM.
ACCESSION #
76350882

 

Related Articles

  • Effect of chemotherapy on survival after whole brain radiation therapy for brain metastases: a single-center retrospective analysis. Mayahara, Hiroshi; Sumi, Minako; Ito, Yoshinori; Sekii, Syuhei; Takahashi, Kana; Inaba, Kouji; Kuroda, Yuuki; Murakami, Naoya; Morota, Madoka; Itami, Jun // Journal of Cancer Research & Clinical Oncology;Jul2012, Vol. 138 Issue 7, p1239 

    Background and purpose: Whether chemotherapy for systemic disease affects survival of patients with brain metastases or not has not been elucidated before. We performed comprehensive analysis of patients with newly-diagnosed brain metastases primarily treated with whole brain radiation therapy...

  • Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. Tejada, Sonia; Díez-Valle, Ricardo; Aldave, Guillermo; Marigil, Miguel; Gallego, Jaime; Domínguez, Pablo // Journal of Neuro-Oncology;Jan2014, Vol. 116 Issue 1, p169 

    Our purpose was to analyze the pattern of failure in glioblastoma (GBM) patients at first recurrence after radiotherapy and temozolomide and its relationship with different factors. From 77 consecutive GBM patients treated at our institution with fluorescence guided surgery and standard...

  • Differential Effects of MicroRNAs on Glioblastoma Growth and Migration. Jeansonne, Duane; Pacifici, Marco; Lassak, Adam; Reiss, Krzysztof; Russo, Giuseppe; Zabaleta, Jovanny; Peruzzi, Francesca // Genes;Mar2013, Vol. 4 Issue 1, p46 

    Glioblastoma multiforme is characterized by rapid proliferation, aggressive metastatic potential, and resistance to radio- and chemotherapy. The matricellular protein CYR61 regulates cellular proliferation and migration and is highly expressed in Glioblastomas. MicroRNAs are 22-nucleotides long...

  • Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. Simó, Marta; Velasco, Roser; Graus, Francesc; Verger, Eugenia; Gil, Miguel; Pineda, Estela; Blasco, Jaume; Bruna, Jordi // Journal of Neuro-Oncology;Jul2012, Vol. 108 Issue 3, p451 

    Epilepsy in glioblastoma multiforme (GBM) patients is common. Hematological toxicity is a potential side effect of antiepileptic drugs (AEDs) and a frequent limiting-dose effect of temozolomide (TMZ). The aim of the study was to investigate the impact of AEDs on thrombocytopenia in GBM patients...

  • Monitoring of Radiochemotherapy in Patients with Glioblastoma Using O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography: Is Dynamic Imaging Helpful? Piroth, Marc D.; Liebenstund, Sarah; Galldiks, Norbert; Stoffels, Gabriele; Shah, Nadim J.; Eble, Michael J.; Coenen, Heinz H.; Langen, Karl-Josef // Molecular Imaging;Sep2013, Vol. 12 Issue 6, p388 

    Monitoring of radiochemotherapy (RCX) in patients with glioblastoma is difficult because unspecific alterations in magnetic resonance imaging with contrast enhancement can mimic tumor progression. Changes in tumor to brain ratios (TBRs) in positron emission tomography (PET) using...

  • Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. Petrecca, Kevin; Guiot, Marie-Christine; Panet-Raymond, Valerie; Souhami, Luis // Journal of Neuro-Oncology;Jan2013, Vol. 111 Issue 1, p19 

    Glioblastomas (GBM) are highly motile cancers that invade through normal brain. In the absence of curative chemotherapy this invasion, beyond surgical and radiotherapy margins, to distant brain sites is thought to be an important cause of treatment failure. Paradoxically, studies analyzing...

  • Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. Champ, Colin; Palmer, Joshua; Volek, Jeff; Werner-Wasik, Maria; Andrews, David; Evans, James; Glass, Jon; Kim, Lyndon; Shi, Wenyin // Journal of Neuro-Oncology;Mar2014, Vol. 117 Issue 1, p125 

    Retrospective data suggests that low serum glucose levels during the treatment of glioblastoma multiforme (GBM) may improve clinical outcomes. As such, many patients are implementing a ketogenic diet (KD) in order to decrease serum glucose flux while simultaneously elevating circulating ketones...

  • Pediatric glioblastoma multiforme: A singleinstitution experience. Ansari, Mansour; Nasrolahi, Hamid; Kani, Amir-Abbas; Mohammadianpanah, Mohammad; Ahmadloo, Niloofar; Omidvari, Shapour; Mosalaei, Ahmad // Indian Journal of Medical & Paediatric Oncology;Jul-Sep2012, Vol. 33 Issue 3, p155 

    Background: Glioblastoma multiforme (GBM) is the most common astrocytoma in adults and has a poor prognosis, with a median survival of about 12 months. But, it is rare in children. We report our experience on the pediatric population (20 years or younger) with GBM. Patients and Methods:...

  • Mouse models of glioblastoma: lessons learned and questions to be answered. Janbazian, Loury; Karamchandani, Jason; Das, Sunit // Journal of Neuro-Oncology;Jun2014, Vol. 118 Issue 1, p1 

    Glioblastoma is the most common primary brain tumour in adults. While many patients achieve disease remission following treatment with surgical resection, radiation therapy and chemotherapy, this remission is brief and invariably followed by tumour recurrence and progression. Recent work using...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics